Garofalo Health Care S.P.A.

As of June 30, 2026, Garofalo Health Care S.P.A. carries a market capitalization of 470.42M, placing it among publicly traded companies globally. Its enterprise value stands at 699.86M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Garofalo Health Care S.P.A.'s next confirmed earnings release is scheduled for December 2, 2026.

As of June 30, 2026, Garofalo Health Care S.P.A. has 88.43M shares outstanding.

As of June 30, 2026, Garofalo Health Care S.P.A. trades at a trailing price-to-earnings ratio of 24.52. The price-to-sales ratio is 0.95, and the price-to-book ratio stands at 1.36.

As of June 30, 2026, Garofalo Health Care S.P.A. trades at an EV/EBITDA multiple of 10.23 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.42 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 17.90 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Garofalo Health Care S.P.A. trades at an EV/FCF ratio of 34.97, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 699.86M versus a market cap of 470.42M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Garofalo Health Care S.P.A. maintains a current ratio of 1.01, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 68.03, indicating elevated leverage, while an interest coverage ratio of 6.36 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Garofalo Health Care S.P.A. posted a return on equity (ROE) of 5.64, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 4.63 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 2.15, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 4.52, useful for judging operating efficiency across full business cycles. The company generates approximately 181,866.91 in revenue per employee across its workforce of 2,712.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 21.94 indicates how many times Garofalo Health Care S.P.A. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Garofalo Health Care S.P.A. recorded 8.53M in income tax expense. That works out to an effective tax rate of 30.68, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 27.80M, leaving 19.17M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Garofalo Health Care S.P.A.'s stock has gained approximately 3.47% over the past 52 weeks. The 50-day moving average sits at 5.44, while the 200-day moving average is 5.30.

Over the twelve months ended June 30, 2026, Garofalo Health Care S.P.A. generated 493.31M in revenue and converted that into 19.17M in net income, yielding earnings per share of 0.22. EBITDA reached 68.38M, while operating income came in at 53.26M.

As of June 30, 2026, Garofalo Health Care S.P.A. holds 24.52M in cash and equivalents against 243.08M in total debt, resulting in a net debt position of 208.50M. Total book value stands at 346.43M, with working capital of 2.38M providing operational flexibility.

Garofalo Health Care S.P.A. produced 55.21M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -42.64M in capital expenditures, free cash flow totaled 12.56M - equivalent to 0.14 per share.

Over the twelve months ended June 30, 2026, Garofalo Health Care S.P.A. posted a gross margin of 71.84, reflecting its pricing power and cost economics. The operating margin of 10.80 and net profit margin of 3.89 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Garofalo Health Care S.P.A. paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 2.67, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 0.29, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Garofalo Health Care S.P.A. shareholders.

As of June 30, 2026, Garofalo Health Care S.P.A. has an Altman Z-Score of 2.23, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.